Celltrion, a major Korean biopharmaceutical firm, said Tuesday its fourth quarter net profit had skyrocketed from a year ...

The EC’s decision was underpinned by a data set and evidence totality, which included findings from a Phase III trial.

Avtozma, which is Celltrion’s twelfth biosimilar to be approved by the EC, is a recombinant humanised monoclonal antibody ...

Celltrion today announced that the European Commission (EC) has granted marketing authorization for Avtozma® (CT-P47), a ...

South Korean firm Celltrion announced that the European Commission (EC) has granted marketing authorization for Avtozma ...

Celltrion's autoimmune disease treatment, Remsima, has surpassed 1.2 trillion won ($837 million) in annual sales, making it ...

Celltrion announces 100 billion won share buyback, starts market purchase tomorrow Celltrion to start market share buyback ...

Celltrion’s Remsima surpassed 1 trillion won ($699 million) in sales last year, making it the first drug developed by a ...

Celltrion announced on the 24th that it has received product approval from the European Commission (EC) for ACTEMRA ...

South Korea-based Celltrion today announced that the European Commission (EC) has granted marketing authorization for three ...

Celltrion today announced that the European Commission (EC) has granted marketing authorization for three products across two biosimilars: Eydenzelt® ...

Celltrion has secured marketing authorisation from the European Commission (EC) for Avtozma (CT-P47), a biosimilar to Chugai Pharmaceutical’s RoActemra (tocilizumab). The approval allows Avtozma ...